Regulatory/Legislative News

The FDA has granted breakthrough device designation to SightGlass Vision’s diffusion optics technology spectacle lenses, which are designed to slow myopia progression in children.

U.S. Reps Cathy McMorris Rodgers and Brett Guthrie have launched an inquiry into abusive marketplace tactics of vision and dental plans, according to the American Optometric Association.

Despite a decrease in total Medicare-allowed payments for laser trabeculoplasty across the U.S. and in three key states from 2015 to 2018, there was an increase in payments by optometrists vs. ophthalmologists, according to research.

The FDA has issued a warning to consumers not to purchase or use South Moon, Rebright or FivFivGo eye drops because of possible contamination and risk for eye infection.

The FDA has agreed to a special protocol assessment agreement modification for Ocular Therapeutix’s phase 3 SOL clinical trial of Axpaxli, an axitinib intravitreal implant for treatment of wet age-related macular degeneration.

A survey conducted after the Jan. 4 American Optometric Association’s virtual townhall highlights optometrists’ concerns about anti-patient, anti-doctor and anti-competitive abuses in the vision plan industry.

The FDA has released a revised draft guidance discussing quality considerations for topical ophthalmic drug products, with the addition of new information related to product sterility and prevention of contamination.

A new proposal in Utah could prohibit the purchase of contact lenses from a prescribing eye doctor, according to a press release from the American Optometric Association.

FDA warnings about potentially contaminated over-the-counter eye drops topped the news on Healio Optometry this year.

Kilitch Healthcare India Limited has voluntarily recalled 25 over-the-counter eye drop products after the FDA warned of unsanitary conditions and potential safety concerns, according to a company press release.